BB Biotech AG provides investment services for biotechnology sector. The company is headquartered in Schaffhausen, Schaffhausen and currently employs 86 full-time employees. The company went IPO on 2006-11-08. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Company’s portfolio comprises between 20 and 35 companies and includes such companies as Celgene, Actelion, Vertex Pharmaceuticals, Gilead, Novo Nordisk, Incyte, Isis Pharmaceuticals, Immunogen, Halozyme Therapeutics, Ariad Pharmaceuticals, Biomarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug, and Idenix Pharmaceuticals.
BBAGF 'in mevcut fiyatı $0 'dir, son işlem günde 0% azalmış etti.
BB Biotech AG için ana iş temaları veya sektörler nelerdir?
BB Biotech AG N/A endüstrisine ait ve sektör N/A 'dir
BB Biotech AG 'in piyasa değerlemesi nedir?
BB Biotech AG 'in mevcut piyasa değerlemesi $NaN 'dir
BB Biotech AG al, sat, yoksa beklemeli mi?
Wall Street analistlerine göre, 7 analist BB Biotech AG için analist derecelendirmeleri gerçekleştirdi, bunlar 3 güçlü al, 6 al, 1 tut, 0 sat ve 3 güçlü sat içermektedir